Watch RLAY. Know when insiders buy.
One email the day a filing lands. Free.
Work order
34
FLAG · insiders 25, shorts 43
Insiders, 90 days
−$116.5M
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.2BP/E —DIV YIELD —FCF YIELD —REV TTM $10.3M +23.9%NET INCOME −$286MNET CASH —52W 3.99 – 20.75NEXT EARNINGS Nov 5 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $350K | −48.3% | — | −$90.8M | −$83.7M | — | -0.41 | −$54.1M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $3M | −60.9% | — | −$78.6M | −$73.3M | — | -0.41 | −$51.1M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $7M | — | — | −$60.6M | −$54.9M | — | -0.31 | −$44.9M | $1K | −$44.9M | Feb 26 |
| Q3 2025 · Sep 30 | $0 | — | — | −$80.4M | −$74.1M | — | -0.43 | −$62.1M | −$1K | −$62.1M | Nov 6 |
| Q2 2025 · Jun 30 | $677K | — | — | −$76.8M | −$70.4M | — | -0.41 | −$55.3M | $26K | −$55.3M | Aug 6 |
| Q1 2025 · Mar 31 | $7.7M | −23.3% | — | −$84.9M | −$77.1M | — | -0.46 | −$73.2M | $384K | −$73.6M | Aug 6 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$85M | −$76M | — | -0.42 | −$57.9M | $0 | −$57.9M | Feb 26 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$96.4M | −$88.1M | — | -0.63 | −$75.1M | $227K | −$75.3M | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$100.8M | −$92.2M | — | -0.69 | −$65.8M | $11K | −$65.8M | Nov 6 |
| Q1 2024 · Mar 31 | $10M | — | — | −$90.4M | −$81.4M | — | -0.62 | −$50.3M | $1.8M | −$52.1M | Nov 6 |
| Q4 2023 · Dec 31derived | −$1K | — | — | −$92.2M | −$83.5M | — | -0.67 | −$89.2M | $118K | −$89.3M | Feb 26 |
| Q3 2023 · Sep 30 | $25.2M | — | — | −$73.6M | −$65.7M | — | -0.54 | −$75.4M | $590K | −$76M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $15.4M | — | −$302.7M | −$276.5M | -1800.6% | -1.61 | −$235.5M | $410K | −$235.9M | — | — |
| FY2024 · to Dec 31 | $10M | — | −$372.5M | −$337.7M | -3374.7% | -2.36 | −$249.1M | $2M | −$251.1M | — | — |
| FY2023 · to Dec 31 | $25.5M | — | −$373M | −$342M | -1338.7% | -2.79 | −$300.3M | $4.1M | −$304.4M | — | — |
| FY2022 · to Dec 31 | $1.4M | — | −$299.3M | −$290.5M | -21036.1% | -2.59 | −$229.5M | $9.1M | −$238.6M | — | — |
| FY2021 · to Dec 31 | $3M | — | −$364.7M | −$363.9M | -12012.9% | -3.82 | −$74.4M | $3.5M | −$77.9M | — | — |
| FY2020 · to Dec 31 | $82.7M | — | −$55.8M | −$52.4M | -63.4% | -5.40 | −$102.5M | $1.9M | −$104.4M | — | — |
Every number comes from Relay Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.